Literature DB >> 2118480

Priming the macrophage respiratory burst with IL-4: enhancement with TNF-alpha but inhibition by IFN-gamma.

W A Phillips1, M Croatto, J A Hamilton.   

Abstract

Pre-exposure to bacterial lipopolysaccharide (LPS) or certain cytokines is known to enhance the ability of murine macrophages to generate a respiratory burst in response to subsequent stimulation, a phenomenon referred to as 'priming'. We report here that the cytokine interleukin-4 (IL-4) can prime murine macrophages. Pretreatment of murine bone marrow-derived macrophages (BMM) with 10 U/ml murine IL-4 for 48 hr was found to enhance the respiratory burst following subsequent stimulation with phorbol myristate acetate (PMA) (10(-6) M) or zymosan (1 mg/ml). Human tumour necrosis factor-alpha (TNF-alpha) (10(-9) M) can also prime BMM for an enhanced respiratory burst and the combination of TNF-alpha and IL-4 resulted in an enhanced (greater than additive) priming effect. In contrast, interferon-gamma (IFN-gamma) (100 U/ml), although by itself capable of priming the BMM respiratory burst, was found to antagonize the priming effects of IL-4. These results demonstrate that IL-4 can be added to the growing list of cytokines capable of modulating the respiratory burst response of macrophages, suggesting a possible role for this cytokine in inflammation and in the host response to infection. The opposing effects of TNF-alpha and IFN-gamma when interacting with IL-4 highlight the difficulties in predicting the effect of a given cytokine in vivo, where potential interactions with other cytokines must be considered.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2118480      PMCID: PMC1384255     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  30 in total

1.  Increased superoxide anion production by immunologically activated and chemically elicited macrophages.

Authors:  R B Johnston; C A Godzik; Z A Cohn
Journal:  J Exp Med       Date:  1978-07-01       Impact factor: 14.307

2.  Oxygen metabolism and the microbicidal activity of macrophages.

Authors:  R B Johnston
Journal:  Fed Proc       Date:  1978-11

Review 3.  Active oxygen species and the functions of phagocytic leukocytes.

Authors:  J A Badwey; M L Karnovsky
Journal:  Annu Rev Biochem       Date:  1980       Impact factor: 23.643

Review 4.  Mechanisms of macrophage antimicrobial activity.

Authors:  C F Nathan
Journal:  Trans R Soc Trop Med Hyg       Date:  1983       Impact factor: 2.184

5.  Production of superoxide, hydrogen peroxide and hydroxyl radicals by phagocytic cells: a cause of chronic inflammatory disease?

Authors:  B Halliwell
Journal:  Cell Biol Int Rep       Date:  1982-06

6.  IL-4 inhibits superoxide production by human mononuclear phagocytes.

Authors:  S L Abramson; J I Gallin
Journal:  J Immunol       Date:  1990-01-15       Impact factor: 5.422

7.  Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma.

Authors:  H W Murray; G L Spitalny; C F Nathan
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

8.  Hydrogen peroxide release from mouse peritoneal macrophages: dependence on sequential activation and triggering.

Authors:  C F Nathan; R K Root
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

9.  Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide.

Authors:  M J Pabst; R B Johnston
Journal:  J Exp Med       Date:  1980-01-01       Impact factor: 14.307

10.  Induction of Fc epsilon R2/CD23 on human epidermal Langerhans cells by human recombinant interleukin 4 and gamma interferon.

Authors:  T Bieber; A Rieger; C Neuchrist; J C Prinz; E P Rieber; G Boltz-Nitulescu; O Scheiner; D Kraft; J Ring; G Stingl
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  11 in total

1.  Mediators of ischemia-reperfusion injury of rat lung.

Authors:  M J Eppinger; G M Deeb; S F Bolling; P A Ward
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Expression of tumor necrosis factor and c-fos genes in peritoneal macrophages of hypothyroid mice.

Authors:  W K Liu
Journal:  Inflammation       Date:  1993-04       Impact factor: 4.092

3.  IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages.

Authors:  P H Hart; R L Cooper; J J Finlay-Jones
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

4.  Gamma interferon is not essential in host defense against disseminated candidiasis in mice.

Authors:  Q Qian; J E Cutler
Journal:  Infect Immun       Date:  1997-05       Impact factor: 3.441

5.  Transiently enhanced LPS-induced fever following hyperthermic stress in rabbits.

Authors:  Masaaki Shibata; Tadashi Uno; Walter Riedel; Michiyo Nishimaki; Kaori Watanabe
Journal:  Int J Biometeorol       Date:  2005-06-28       Impact factor: 3.787

6.  Inhibition of macrophage-activating cytokines is beneficial in the acute septic response.

Authors:  H P Redmond; K D Chavin; J S Bromberg; J M Daly
Journal:  Ann Surg       Date:  1991-10       Impact factor: 12.969

7.  Zymosan-triggered tyrosine phosphorylation in mouse bone-marrow-derived macrophages is enhanced by respiratory-burst priming agents.

Authors:  S P Green; J A Hamilton; W A Phillips
Journal:  Biochem J       Date:  1992-12-01       Impact factor: 3.857

8.  In vitro effects of interleukin-4 on interferon-gamma-induced macrophage activation.

Authors:  R Appelberg; I M Orme; M I Pinto de Sousa; M T Silva
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

9.  Interleukin 4 regulates induction of sialoadhesin, the macrophage sialic acid-specific receptor.

Authors:  A S McWilliam; P Tree; S Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  Entamoeba histolytica proteins modulate the respiratory burst potential by murine macrophages.

Authors:  J Y Lin; K Keller; K Chadee
Journal:  Immunology       Date:  1993-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.